US4233333A - 4,5-Dimethyl-thieno[3,2-d]isothiazolo-3(2H)-one-1,1-dioxides, compositions, and methods of use as a sweetener - Google Patents
4,5-Dimethyl-thieno[3,2-d]isothiazolo-3(2H)-one-1,1-dioxides, compositions, and methods of use as a sweetener Download PDFInfo
- Publication number
- US4233333A US4233333A US05/952,958 US95295878A US4233333A US 4233333 A US4233333 A US 4233333A US 95295878 A US95295878 A US 95295878A US 4233333 A US4233333 A US 4233333A
- Authority
- US
- United States
- Prior art keywords
- methyl
- dioxide
- isothiazole
- thieno
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 35
- 238000000034 method Methods 0.000 title claims description 7
- 239000003765 sweetening agent Substances 0.000 title abstract description 18
- 235000003599 food sweetener Nutrition 0.000 title abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 7
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 7
- 150000007529 inorganic bases Chemical class 0.000 claims abstract description 5
- 150000007530 organic bases Chemical class 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 4
- 239000001257 hydrogen Substances 0.000 abstract description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 3
- 150000002431 hydrogen Chemical group 0.000 abstract description 3
- 229910052717 sulfur Chemical group 0.000 abstract description 3
- 239000011593 sulfur Chemical group 0.000 abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 66
- 239000000243 solution Substances 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 17
- 239000007858 starting material Substances 0.000 description 17
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- LKDBZFCQBQTOMF-UHFFFAOYSA-N 5-methyl-1,1-dioxothieno[3,2-d][1,2]thiazol-3-one Chemical compound O=C1NS(=O)(=O)C2=C1C=C(C)S2 LKDBZFCQBQTOMF-UHFFFAOYSA-N 0.000 description 14
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 239000001569 carbon dioxide Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 229960004793 sucrose Drugs 0.000 description 9
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 9
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 9
- SWVCQVNUHZERAO-UHFFFAOYSA-N 5-methyl-2-sulfamoylthiophene-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=C(S(N)(=O)=O)S1 SWVCQVNUHZERAO-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- AYJBBGBSFGTACW-UHFFFAOYSA-N 4,5-dimethyl-1,1-dioxothieno[3,2-d][1,2]thiazol-3-one Chemical compound CC1=C(C)SC2=C1C(=O)NS2(=O)=O AYJBBGBSFGTACW-UHFFFAOYSA-N 0.000 description 7
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 235000013681 dietary sucrose Nutrition 0.000 description 7
- 229940081974 saccharin Drugs 0.000 description 7
- 235000019204 saccharin Nutrition 0.000 description 7
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 7
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 231100000243 mutagenic effect Toxicity 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 229920000137 polyphosphoric acid Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000003505 mutagenic effect Effects 0.000 description 5
- -1 phenoxy, naphthoxy Chemical group 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- OMMCMKPQXHWSEC-UHFFFAOYSA-N 2-sulfamoylthiophene-3-carboxylic acid Chemical compound NS(=O)(=O)C=1SC=CC=1C(O)=O OMMCMKPQXHWSEC-UHFFFAOYSA-N 0.000 description 4
- RRKNQVUHOYVZOS-UHFFFAOYSA-N 5-methyl-2-sulfamoylfuran-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=C(S(N)(=O)=O)O1 RRKNQVUHOYVZOS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010013911 Dysgeusia Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010028400 Mutagenic effect Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- XQQBUAPQHNYYRS-UHFFFAOYSA-N 2-methylthiophene Chemical compound CC1=CC=CS1 XQQBUAPQHNYYRS-UHFFFAOYSA-N 0.000 description 3
- HYUMQPHCOCCQBH-UHFFFAOYSA-N 5-ethyl-1,1-dioxothieno[3,2-d][1,2]thiazol-3-one Chemical compound O=C1NS(=O)(=O)C2=C1C=C(CC)S2 HYUMQPHCOCCQBH-UHFFFAOYSA-N 0.000 description 3
- JFAOVYDFYSSZPX-UHFFFAOYSA-N 5-methyl-1,1-dioxofuro[3,2-d][1,2]thiazol-3-one Chemical compound O=C1NS(=O)(=O)C2=C1C=C(C)O2 JFAOVYDFYSSZPX-UHFFFAOYSA-N 0.000 description 3
- DQGFTLMDQGSPMZ-UHFFFAOYSA-N 5-methyl-1,1-dioxothieno[3,2-d][1,2]thiazol-3-one;sodium Chemical compound [Na].O=C1NS(=O)(=O)C2=C1C=C(C)S2 DQGFTLMDQGSPMZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- QENGPZGAWFQWCZ-UHFFFAOYSA-N Methylthiophene Natural products CC=1C=CSC=1 QENGPZGAWFQWCZ-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- OJBCLISPGGXOIP-UHFFFAOYSA-N methyl 5-methyl-2-sulfamoylthiophene-3-carboxylate Chemical compound COC(=O)C=1C=C(C)SC=1S(N)(=O)=O OJBCLISPGGXOIP-UHFFFAOYSA-N 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000021092 sugar substitutes Nutrition 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- UDQRIYPVPXJQCQ-UHFFFAOYSA-N 1,1-dioxothieno[3,2-d][1,2]thiazol-3-one Chemical compound S1C=CC2=C1S(=O)(=O)NC2=O UDQRIYPVPXJQCQ-UHFFFAOYSA-N 0.000 description 2
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 2
- HLPIHRDZBHXTFJ-UHFFFAOYSA-N 2-ethylfuran Chemical compound CCC1=CC=CO1 HLPIHRDZBHXTFJ-UHFFFAOYSA-N 0.000 description 2
- JCCCMAAJYSNBPR-UHFFFAOYSA-N 2-ethylthiophene Chemical compound CCC1=CC=CS1 JCCCMAAJYSNBPR-UHFFFAOYSA-N 0.000 description 2
- TUIYJPZHNFTHNY-UHFFFAOYSA-N 4,5-dimethyl-1,1-dioxofuro[3,2-d][1,2]thiazol-3-one Chemical compound CC1=C(C)OC2=C1C(=O)NS2(=O)=O TUIYJPZHNFTHNY-UHFFFAOYSA-N 0.000 description 2
- BVAPHSFEEPDWDA-UHFFFAOYSA-N 4,5-dimethyl-1,1-dioxothieno[3,2-d][1,2]thiazol-3-one;sodium Chemical compound [Na].CC1=C(C)SC2=C1C(=O)NS2(=O)=O BVAPHSFEEPDWDA-UHFFFAOYSA-N 0.000 description 2
- HXOOBZJVFPFQOU-UHFFFAOYSA-N 4,5-dimethyl-2-sulfamoylfuran-3-carboxylic acid Chemical compound CC=1OC(S(N)(=O)=O)=C(C(O)=O)C=1C HXOOBZJVFPFQOU-UHFFFAOYSA-N 0.000 description 2
- GYMVKDPWTIVYLZ-UHFFFAOYSA-N 4,5-dimethyl-2-sulfamoylthiophene-3-carboxylic acid Chemical compound CC=1SC(S(N)(=O)=O)=C(C(O)=O)C=1C GYMVKDPWTIVYLZ-UHFFFAOYSA-N 0.000 description 2
- GJWPHKSVOLAGIJ-UHFFFAOYSA-N 4-ethyl-5-methyl-1,1-dioxothieno[3,2-d][1,2]thiazol-3-one Chemical compound O=C1NS(=O)(=O)C2=C1C(CC)=C(C)S2 GJWPHKSVOLAGIJ-UHFFFAOYSA-N 0.000 description 2
- FHAGIYWECRXPAO-UHFFFAOYSA-N 5-ethyl-1,1-dioxothieno[3,2-d][1,2]thiazol-3-one;sodium Chemical compound [Na].O=C1NS(=O)(=O)C2=C1C=C(CC)S2 FHAGIYWECRXPAO-UHFFFAOYSA-N 0.000 description 2
- ABEJRLXHISBMSO-UHFFFAOYSA-N 5-ethyl-2-sulfamoylfuran-3-carboxylic acid Chemical compound CCC1=CC(C(O)=O)=C(S(N)(=O)=O)O1 ABEJRLXHISBMSO-UHFFFAOYSA-N 0.000 description 2
- BGUKCJHNIOIUTM-UHFFFAOYSA-N 5-methyl-1,1-dioxo-1,2-benzothiazol-3-one Chemical compound CC1=CC=C2S(=O)(=O)NC(=O)C2=C1 BGUKCJHNIOIUTM-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000010513 Stupor Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000037429 base substitution Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- BGWIWVOKLJAZQH-UHFFFAOYSA-N calcium;4,5-dimethyl-1,1-dioxothieno[3,2-d][1,2]thiazol-3-one Chemical compound [Ca].CC1=C(C)SC2=C1C(=O)NS2(=O)=O BGWIWVOKLJAZQH-UHFFFAOYSA-N 0.000 description 2
- IKUCDMIRAGEZRN-UHFFFAOYSA-N calcium;5-methyl-1,1-dioxothieno[3,2-d][1,2]thiazol-3-one Chemical compound [Ca].O=C1NS(=O)(=O)C2=C1C=C(C)S2 IKUCDMIRAGEZRN-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- UWSJKYHYYQWTMK-UHFFFAOYSA-N n-tert-butyl-5-ethylthiophene-2-sulfonamide Chemical compound CCC1=CC=C(S(=O)(=O)NC(C)(C)C)S1 UWSJKYHYYQWTMK-UHFFFAOYSA-N 0.000 description 2
- XTVBERKJXVKITC-UHFFFAOYSA-N n-tert-butyl-5-methylfuran-2-sulfonamide Chemical compound CC1=CC=C(S(=O)(=O)NC(C)(C)C)O1 XTVBERKJXVKITC-UHFFFAOYSA-N 0.000 description 2
- KUBVQTGUUQATJS-UHFFFAOYSA-N n-tert-butyl-5-methylthiophene-2-sulfonamide Chemical compound CC1=CC=C(S(=O)(=O)NC(C)(C)C)S1 KUBVQTGUUQATJS-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- WDADTRKXPFEHLP-UHFFFAOYSA-M sodium;5-methylfuran-2-sulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)O1 WDADTRKXPFEHLP-UHFFFAOYSA-M 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical group OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- JJIBEXZGSXIQBV-UHFFFAOYSA-N 1,1-dioxo-1,2-thiazol-3-one Chemical class O=C1NS(=O)(=O)C=C1 JJIBEXZGSXIQBV-UHFFFAOYSA-N 0.000 description 1
- JLHMJWHSBYZWJJ-UHFFFAOYSA-N 1,2-thiazole 1-oxide Chemical compound O=S1C=CC=N1 JLHMJWHSBYZWJJ-UHFFFAOYSA-N 0.000 description 1
- FJSKXQVRKZTKSI-UHFFFAOYSA-N 2,3-dimethylfuran Chemical compound CC=1C=COC=1C FJSKXQVRKZTKSI-UHFFFAOYSA-N 0.000 description 1
- BZYUMXXOAYSFOW-UHFFFAOYSA-N 2,3-dimethylthiophene Chemical compound CC=1C=CSC=1C BZYUMXXOAYSFOW-UHFFFAOYSA-N 0.000 description 1
- RBRAJDCWXUJHIY-UHFFFAOYSA-N 3-ethyl-2-methylthiophene Chemical compound CCC=1C=CSC=1C RBRAJDCWXUJHIY-UHFFFAOYSA-N 0.000 description 1
- SDBGUTJYVVQBST-UHFFFAOYSA-N 4,5-dimethyl-2-sulfamoyl-3h-furan-2-carboxylic acid Chemical compound CC1=C(C)OC(S(N)(=O)=O)(C(O)=O)C1 SDBGUTJYVVQBST-UHFFFAOYSA-N 0.000 description 1
- FYJYATBLABVTJO-UHFFFAOYSA-N 4,5-dimethylthiophene-2-sulfonyl chloride Chemical compound CC=1C=C(S(Cl)(=O)=O)SC=1C FYJYATBLABVTJO-UHFFFAOYSA-N 0.000 description 1
- PAXPLEPDHQVVBM-UHFFFAOYSA-N 5-ethyl-1,1-dioxofuro[3,2-d][1,2]thiazol-3-one Chemical compound O=C1NS(=O)(=O)C2=C1C=C(CC)O2 PAXPLEPDHQVVBM-UHFFFAOYSA-N 0.000 description 1
- ZYYYNLBAPRPHSX-UHFFFAOYSA-N 5-ethylfuran-2-sulfonic acid Chemical compound CCC1=CC=C(S(O)(=O)=O)O1 ZYYYNLBAPRPHSX-UHFFFAOYSA-N 0.000 description 1
- UWDPICCHGRNBRX-UHFFFAOYSA-N 5-methyl-1,1-dioxofuro[3,2-d][1,2]thiazol-3-one;sodium Chemical compound [Na].O=C1NS(=O)(=O)C2=C1C=C(C)O2 UWDPICCHGRNBRX-UHFFFAOYSA-N 0.000 description 1
- RYDFZEOJDTWFHA-UHFFFAOYSA-N 5-methyl-1,1-dioxothieno[3,2-d][1,2]thiazol-3-one;potassium Chemical compound [K].O=C1NS(=O)(=O)C2=C1C=C(C)S2 RYDFZEOJDTWFHA-UHFFFAOYSA-N 0.000 description 1
- YNNRJWKCQVUBDZ-UHFFFAOYSA-N 5-methylfuran-2-sulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)O1 YNNRJWKCQVUBDZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N Cyclohexane Natural products CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- YSRHGYLLQFXTCJ-UHFFFAOYSA-N azane 5-methyl-1,1-dioxothieno[3,2-d][1,2]thiazol-3-one Chemical compound N.O=C1NS(=O)(=O)C2=C1C=C(C)S2 YSRHGYLLQFXTCJ-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 229960002456 hexobarbital Drugs 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- OBYTYHRKLLTSRC-UHFFFAOYSA-N n-tert-butyl-5-ethylfuran-2-sulfonamide Chemical compound CCC1=CC=C(S(=O)(=O)NC(C)(C)C)O1 OBYTYHRKLLTSRC-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- JGCJBLODDCFDDI-UHFFFAOYSA-M sodium;4,5-dimethylfuran-2-sulfonate Chemical compound [Na+].CC=1C=C(S([O-])(=O)=O)OC=1C JGCJBLODDCFDDI-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/34—Sugar alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- This invention relates to novel condensed isothiazolo-3(2H)-one-1, 1-dioxides and salts thereof, a method of preparing these compounds, and methods of using them as sweetening agents.
- the present invention relates to a novel class of compounds represented by the formula ##STR2## wherein X is oxygen or sulfur;
- R 1 is hydrogen, methyl or ethyl
- R 2 is methyl or ethyl
- R 1 and R 2 have the same meanings as in formula I;
- R 3 is hydrogen or tert. alkyl of 4 to 19 carbon atoms
- R 4 is a nucleophilic exchangeable substituent, such as hydroxyl, alkoxy of 1 to 10 carbon atoms, phenoxy, naphthoxy, halogen, phenyl-(alkoxy of 1 to 3 carbon atoms) or naphthyl-(alkoxy of 1 to 3 carbon atoms);
- the end product is treated at tempertures between 0° and 100° C., preferably at 50° to 70° C., with an acid, such as phosphoric acid, polyphosphoric acid, sulfuric acid or a mixture of any two or more of these, whereby a cyclization occurs.
- the end product is isolated in conventional manner, for instance, by addition of ice to the reaction mixture and purification of the precipitate formed thereby.
- the cyclization may, however, also be effected in the absence of a mineral acid by simple heating to temperatures between 100° and 250° C., for instance also in the presence of a solvent such as o-dichloro-benzene or toluene.
- a solvent such as o-dichloro-benzene or toluene.
- basic reaction conditions for example reaction in the presence of sodium methylate, have proved to be equally suitable.
- the starting compounds of the formula II can, for example, be obtained as follows: From the correspondingly substituted thiophene or furan the corresponding sulfochloride is prepared with chlorosulfonic acid and phosphorus pentachloride. The sulfochloride is then reacted with an amine of the formula H 2 N--R 3 , where R 3 has the meanings previously defined, to form a sulfonamide of the formula ##STR4## wherein R 1 , R 2 , R 3 and X have the meanings previously defined.
- the sulfonamide is thereupon treated, for instance in dry tetrahydrofuran or an analogous ether as a solvent medium, with a lithium alkyl such as n-butyl lithium, which is dissolved in a hydrocarbon such as hexane, at temperatures of about -40° C., and subsequently reacted with carbon dioxide at -60° C.
- a lithium alkyl such as n-butyl lithium
- a hydrocarbon such as hexane
- the reaction product i.e. the corresponding 2-sulfamoyl-3-carboxylic acid derivative of the formula II is liberated and in conventional manner isolated and purified.
- the starting compound of the formula II wherein R 1 is hydrogen, R 2 is methyl, R 3 is tert. alkyl and X is sulfur can be obtained in this manner with a total yield of 60 to 70% of theory from 2-methyl-thiophene.
- the condensed isothiazolo-3(2H)-one-1,1-dioxides of the formula I are acid compounds and form salts with inorganic or organic bases.
- non-toxic, physiologically acceptable salts are those formed with an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, an alkaline earth metal hydroxide such as calcium hydroxide, or ammonium hydroxide.
- the starting compound was obtained in the following way: 1 liter of ethylene chloride was admixed with 260 gm (3.17 mol) of 2-methyl-furan and 507 gm (3.17 mol) of sulfur trioxide-pyridine complex, and the mixture was stirred for 3 days. The reaction mixture was then admixed with 3 liters of warm water while stirring, and the aqueous phase was separated and, by means of sodium carbonate, adjusted to a pH-value of 7.5 and then evaporated to dryness. The residue was extracted several times with isopropanol by refluxing, and from the combined and cooled isopropanol fractions 248 gm (43% of theory) of crystalline sodium 5-methyl-furan-2-sulfonate was obtained.
- Boiling stones and 42 gm (0.12 mol) of 2-(N-tert. butyl)-sulfamoyl-5-methyl-furan-3-carboxylic acid were heated in a round bottom flask for 2 hours at 150° C.
- the cooled reaction mixture was taken up in 1 liter of ethyl acetate. After refluxing the solution was treated with activated charcoal, filtered and evaporated. 22.8 gm (69% of theory) of crystalline 5-methyl-2-sulfamoyl-furan-3-carboxylic acid were obtained.
- the starting compound was prepared in the following way:
- the starting compound was prepared in the following way:
- the starting compound was prepared as follows:
- the starting compound was prepared in the following way:
- the starting compound was prepared as follows: 22.0 gm (0.196 mol) of 2,3-dimethyl-thiophene were converted into 25.0 gm of N-tert.butyl-4,5-dimethyl-thiophene-2-sulfonamide in analogy to the conversion of 2-ethyl-thiophene (see starting compound of Example 7) with chlorosulfonic acid/phosphorus pentachloride via 4,5-dimethyl-thiophene-2-sulfonic acid chloride and then with tert.butylamine. Yield: 51.5% of theory.
- R f -value 0.19 (TLC-prefabricated plates, silica gel 60 F 254 , thickness of the layer 0.25 mm; eluant:ethylene chloride/ethyl acetate/glacial acetic acid 100:30:5).
- the starting compound was prepared as follows:
- the compounds of the present invention that is, those embraced by formula I and their non-toxic salts, are useful as sweetening agents.
- the alkyl substituent R 2 in the molecule of the dioxides of the present invention significantly contributes toward an improvement in taste; for instance, they do not have the unpleasant after-taste associated with saccharin. Moreover, the presence of the alkyl group in the 5-position provides a different metabolization route, wherefore the novel compounds exhibit a different toxicologic and metabolic behavior.
- the compounds of the present invention were tested for sweetening power in comparison to certain prior art compounds, as well as for pharmacological effects, toxicity and mutagenic effects, as described below, and the results of these tests for a few representative species were as follows, where
- the relative sweetening power (often also defined as degree of sweetness) of sweetening agents in comparison to saccharose (cane sugar) varies with the concentrations within wide limits.
- concentrations corresponding to a 2-10% solution of saccharose
- the relative sweetening power of saccharin varies from 200 to 700. Therefore, for the determination of the relative sweetening power of the above-mentioned compounds a 3% aqueous solution of saccharose was always used for comparison.
- sweetening agents heretofore known do not have the taste quality of saccharose. They often have a side-taste or after-taste. Novel compounds A to F are, however, characterized by a very pure sweet taste. The compounds A and C achieve the taste quality of saccharose (cane sugar).
- mice show no muscle-relaxing and coordination inhibitory effects in mice; even at dosages of 200 mgm/kg p.o. the mice were able to hold themselves in rotating cylinders.
- the motility of mice was tested in light beam cages; here it could also be determined that compound C does not influence the spontaneous motility of mice.
- Compound C has no effect on the hexobarbital narcosis in mice. At a dose of 25 mgm/kg p.o. the duration of the loss of the righting reflex was tested; the duration of the narcosis was not influenced.
- Compound C also does not influence the electroshock convulsion in mice (dosage 200 mgm/kg p.o.). It also has no influence on the hypothermia of male mice, which is caused by reserpine. Compound C does not cause any ulcerations in the intestinal tract of the rat when 3 times 200 mgm/kg p.o. of the substance are administered.
- the test regarding the local compatibility in the eye of the rabbit showed the following result: a 1% solution causes no mydriasis, no redness of the conjunctiva and no local anesthesia.
- the compound C had no effect on the contractility and the frequency of the isolated, beating atrium of the rat heart.
- compound C was given in doses of 1.0 and 3.0 and 10.0 mg/kg i.v. no effect on blood pressure, heart rate and respiration of anesthetized cats could be observed.
- concentrations of 1 ⁇ 10 -4 mol/liter compound C had no effect on the ADP-induced, thrombine-induced and collagen-induced aggregation of the thrombozytes in the platelet-rich plasma of healthy test persons.
- the acute toxicity was determined after oral administration to male and female mice and to male and female rats.
- the substances were given in an aqueous solution or as a suspension in tylose.
- the following table shows the animals which died within 1 to 7 days after administration of the doses indicated:
- sweetening agents these substances must be harmless and safe. Most of the sweetening agents however, do not meet with this requirement. Thus, for example, saccharin shows a mutagenic effect [R. P. Batzinger, S.-Y. L. On and E. Bueding, Science 198, 944 (1977)], which casts a doubt on its use as a sweetening agent.
- the tests for all microorganisms were carried out in a way such that the influence of a microsomal enzyme system, together with the corresponding co-factors, could be tested with regard to the test substance, and to determine the differences in enzyme induction.
- the tests were performed without an activating system and in the presence of an activating system.
- S-9 supernatants fraction of the endoplasmatic reticulum
- Aroclor 1254 500 mg/kg
- the substance concentrations of compound C were 0.1 and 0.5 mgm/plate and the concentrations of compound D were 5, 10, 15 and 20 mg/plate. In a previous series dilution essay, the highest dosages still did not show any inhibition of the microorganism growth.
- the compounds of the present invention are incorporated into conventional sugar-substitute compositions, such as tablets, powders or solutions, in amounts sufficient to provide the desired sweetening power.
- the solution is compounded from the following ingredients:
- the sweetening ingredient, the sorbic acid, the citric acid and the disodium phosphate are successively dissolved in the distilled water at 60° C. while stirring.
- 1 ml (corresponding to about 20 drops) of the solution contains 20 mgm of the sweetening ingredient and is equal in sweetening power to about 2 lumps of sugar.
- the tablet composition is compounded from the following ingredients:
- the sweetening ingredient is intimately admixed with the sodium bicarbonate and the sorbitol, and the mixture is compressed at no more than 60% relative humidity into 50 mgm-tablets.
- Each tablet contains 5 mgm of the sweetening ingredient and is equivalent in sweetening power to about one lump of sugar.
- any one of the other compounds embraced by formula I or a non-toxic salt thereof may be substituted for the particular sweetening ingredient in Examples 12 and 13.
- the amount of sweetening ingredient in these illustrative examples may be varied to achieve the desired sweetening power, and the amounts and nature of the inert carrier ingredients may be varied to meet particular requirements.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Seasonings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polymerisation Methods In General (AREA)
Abstract
Compounds of the formula <IMAGE> wherein X is oxygen or sulfur; R1 is hydrogen, methyl or ethyl; and R2 is methyl or ethyl; and non-toxic, physiologically acceptable salts thereof formed with an inorganic or organic base. The compounds as well as their salts are useful as sweetening agents.
Description
This invention relates to novel condensed isothiazolo-3(2H)-one-1, 1-dioxides and salts thereof, a method of preparing these compounds, and methods of using them as sweetening agents.
More particularly, the present invention relates to a novel class of compounds represented by the formula ##STR2## wherein X is oxygen or sulfur;
R1 is hydrogen, methyl or ethyl; and
R2 is methyl or ethyl;
and non-toxic, physiologically acceptable salts thereof formed with an inorganic or organic base.
Recent toxicological investigations have shown that the use of cyclamate and saccharin as sweetening agents at higher dosage levels is not entirely safe. At the present time, however, there is no substitute for these sweetening agents on the market. Also, tests with certain natural substances or dipeptides or oxathiazinone-dioxides have until now failed to provide acceptable successor products which can fully and completely replace the heretofore conventional sugar substitutes with respect to safety, high sweetening power and absence of unpleasant after-taste.
Thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide is disclosed as a sweetening agent in German Offenlegungsschrift No. 2,534,689.
5-Methyl-saccharin is disclosed in J. Org. Chem 36, 1843 (1971).
It is an object of the present invention to provide novel sweetening agents which are at least equivalent in sweetening power to previously used sugar substitutes and, in addition, are characterized by the absence of unpleasant after-taste and toxic side-effects.
Other objects and advantages of the instant invention will become apparent as the description thereto proceeds.
We have discovered that the above object is achieved by providing the condensed isothiazolo-3(2H)-one-1,1-dioxides of the formula I above and their non-toxic salts formed with inorganic or organic bases.
The compounds embraced by formula I may be prepared by the following method:
A 2-sulfamoyl-3-carboxylic acid derivative of furan or thiophene of the formula ##STR3##
R1 and R2 have the same meanings as in formula I;
R3 is hydrogen or tert. alkyl of 4 to 19 carbon atoms; and
R4 is a nucleophilic exchangeable substituent, such as hydroxyl, alkoxy of 1 to 10 carbon atoms, phenoxy, naphthoxy, halogen, phenyl-(alkoxy of 1 to 3 carbon atoms) or naphthyl-(alkoxy of 1 to 3 carbon atoms);
is treated at tempertures between 0° and 100° C., preferably at 50° to 70° C., with an acid, such as phosphoric acid, polyphosphoric acid, sulfuric acid or a mixture of any two or more of these, whereby a cyclization occurs. The end product is isolated in conventional manner, for instance, by addition of ice to the reaction mixture and purification of the precipitate formed thereby.
The cyclization may, however, also be effected in the absence of a mineral acid by simple heating to temperatures between 100° and 250° C., for instance also in the presence of a solvent such as o-dichloro-benzene or toluene. Also basic reaction conditions, for example reaction in the presence of sodium methylate, have proved to be equally suitable.
The starting compounds of the formula II can, for example, be obtained as follows: From the correspondingly substituted thiophene or furan the corresponding sulfochloride is prepared with chlorosulfonic acid and phosphorus pentachloride. The sulfochloride is then reacted with an amine of the formula H2 N--R3, where R3 has the meanings previously defined, to form a sulfonamide of the formula ##STR4## wherein R1, R2, R3 and X have the meanings previously defined. The sulfonamide is thereupon treated, for instance in dry tetrahydrofuran or an analogous ether as a solvent medium, with a lithium alkyl such as n-butyl lithium, which is dissolved in a hydrocarbon such as hexane, at temperatures of about -40° C., and subsequently reacted with carbon dioxide at -60° C. After acidifying the reaction mixture with hydrochloric acid, the reaction product, i.e. the corresponding 2-sulfamoyl-3-carboxylic acid derivative of the formula II is liberated and in conventional manner isolated and purified. For example, we have found that the starting compound of the formula II wherein R1 is hydrogen, R2 is methyl, R3 is tert. alkyl and X is sulfur can be obtained in this manner with a total yield of 60 to 70% of theory from 2-methyl-thiophene.
The condensed isothiazolo-3(2H)-one-1,1-dioxides of the formula I are acid compounds and form salts with inorganic or organic bases. Examples of non-toxic, physiologically acceptable salts are those formed with an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, an alkaline earth metal hydroxide such as calcium hydroxide, or ammonium hydroxide.
The following examples illustrate the present invention and will enable others skilled in the art to understand it more completely. It should be understood, however, that the invention is not limited solely to the particular examples given below.
A mixture consisting of 20.5 gm (0.1 mol) of 5-methyl-2-sulfamoyl-furan-3-carboxylic acid, 20.8 gm (0.1 mol) of phosphorus pentachloride and 50 ml of anhydrous toluene was refluxed for eight hours. Thereafter, the hot reaction mixture was filtered, and upon cooling of the filtrate 11.8 gm (62.5% of theory) of 5-methyl-furo[3,2-d]isothiazole-3(2H)-one-1,1-dioxide of the formula ##STR5## crystallized out. The product was recrystallized twice from benzene, yielding 6.9 gm (37% of theory) of the purified product having a melting point of 195°-196° C. (decomp.).
Analysis:
IR (KBr): 1730 and 1690 cm-1 (CO);
1 H-NMR (CDCl3 +CD3 OD): δ=6.5 (s, 1, 4-H), 2.5 (s, 3, CH3) and 1 exchangeable proton:
MS: M+ 187 m/e.
C6 H5 NO4 S (187.18)--Calc.; C-38.50%; H-2.69%; N-7.48%; S-17.13%; Found: C-38.80%; H-2.75%; N-7.46%; S-17.35%.
The starting compound was obtained in the following way: 1 liter of ethylene chloride was admixed with 260 gm (3.17 mol) of 2-methyl-furan and 507 gm (3.17 mol) of sulfur trioxide-pyridine complex, and the mixture was stirred for 3 days. The reaction mixture was then admixed with 3 liters of warm water while stirring, and the aqueous phase was separated and, by means of sodium carbonate, adjusted to a pH-value of 7.5 and then evaporated to dryness. The residue was extracted several times with isopropanol by refluxing, and from the combined and cooled isopropanol fractions 248 gm (43% of theory) of crystalline sodium 5-methyl-furan-2-sulfonate was obtained.
At a temperature of 30° to 50° C., 248 gm (1.35 mol) of sodium 5-methyl-furan-2-sulfonate were admixed in portions with 281 gm (1.35 mol) of phosphorus pentachloride and the mixture was stirred for 15 minutes at 50° C. The reaction mixture was then poured over ice and extracted with ether. The ether phase was washed until neutral, dried and evaporated. The residue (200 gm of 5-methyl-furan-2-sulfonic acid chloride) was dissolved in 500 ml of ether, and the solution was added dropwise to a solution of 280 ml (2.7 mol) of tert.-butylamine in 500 ml of ether at a temperature of 5° to 10° C. After stirring at room temperature and at reflux temperature, each for 2 hours, the reaction mixture was washed with ice water, dilute hydrochloric acid and water and then evaporated. The residue was recrystallized from cyclohexane, yielding 180.5 gm (61.5% of theory) of N-tert. butyl-5 -methyl-furan-2-sulfonamide. M.p. 113°-114° C.
1H-NMR (CDCl3): δ=6.9 (d, 1, J=2 Hz, 3-H), 6.1 (d,1,J=2 Hz, 4-H), 4.6 (s, 1, NH, exchangeable), 2.37 (s,3, CH3), 1.25 (s, 9, C(CH3)3);
C9 H15 NO3 S (217.29)--Calc.: C-49.75%; H-6.94%; N-6.43%; S-14.71%; Found: C-49.50% H-6.97%; N-6.47%; S-15.00%.
500 ml of a 15% solution of butyl lithium (52.5 gm or 0.82 mol) in hexane were added dropwise to a solution of 81 gm (0.37 mol) of N-tert. butyl-5-methyl-furan-2-sulfonamide (cooled to -60° C.) in 1 liter of anhydrous tetrahydrofuran. The reaction mixture was warmed to -20° C. within 2 hours and stirred for 20 minutes at this temperature. Subsequently, the mixture was cooled to -60° C. and a stream of carbon dioxide was introduced slowly. When the exothermic reaction had subsided, the mixture was heated to -20° C. and carefully (evolution of CO2) 136 ml of a semi-concentrated (about 18%) hydrochloric acid were added dropwise, whereby the temperature rose to 0° C. The reaction mixture was then substantially evaporated and stirred into an aqueous sodium bicarbonate solution. The aqueous solution was extracted with ether, acidified to a pH-value of 1 to 2 by means of hydrochloric acid and extracted twice with ether. The acidic ether extracts were dried and evaporated. The obtained crude product was recrystallized from benzene, yielding 81.1 gm (84% of theory) of 2-(N-tert. butyl)-sulfamoyl-5-methyl-furan-3-carboxylic acid.
M.p. 130° C.
IR (CH2 Cl2): 1730 and 1690 cm-1 (CO); 1H-NMR (CDCl3):δ=6.55 (d, 1, J=0.5 Hz, 4-H), 5.7 (s, 1, NH, exchangeable), 2.36 (d, 3, J=0.5 Hz, CH3), 1.25 (s, 9, C(CH3)3) and 1 further exchangeable proton;
C10 H15 NO5 S (261.30)--Calc.: C-45.97%; H-5.79%; N-5.36% S-12.27%; Found: C-46.30%; H-5.88%; N-5.18%; S-12.20%.
Boiling stones and 42 gm (0.12 mol) of 2-(N-tert. butyl)-sulfamoyl-5-methyl-furan-3-carboxylic acid were heated in a round bottom flask for 2 hours at 150° C. The cooled reaction mixture was taken up in 1 liter of ethyl acetate. After refluxing the solution was treated with activated charcoal, filtered and evaporated. 22.8 gm (69% of theory) of crystalline 5-methyl-2-sulfamoyl-furan-3-carboxylic acid were obtained.
M.p. 191° C.
C6 H7 NO5 S (205.20) Calc.: C-35.12%; H-3.44%; N-6.83%; S-15.63%; Found: C-34.95%; H-3.50%; N-6.88%; S-16.00%.
1.0 gm (5.3 millimols) of 5-methyl-furo[3,2-d]isothiazole-3(2H)-one-1, 1-dioxide and 230 mgm (5.3 millimols) of a 55% sodium hydride-in-oil dispersion were refluxed for 1.5 hours in 100 ml of anhydrous tetrahydrofuran. After cooling, the obtained crystals were suction-filtered off, washed with petroleum ether and dried over phosphorus pentoxide, yielding 1.05 gm (95% of theory) of 5-methyl-furo[3,2-d]isothiazole-3-(2H)-one-1,1-dioxide-sodium salt.
M.p. above 280° C. (decomp. starts at 210° C.).
C6 H4 NNaO4 S (209.61)--Calc.: C-34.45%; H-1.93%; N-6.70%; S-15.33%; Found: C-34.20%; H-2.08%; N-6.56%; S-15.30%.
5.0 gm (0.023 mol) of 5-ethyl-2-sulfamoyl-furan-3-carboxylic acid were admixed with 4.75 gm (0.023 mol of phosphorus pentachloride in 300 ml of anhydrous toluene, and the mixture was refluxed for 8 hours. After filtering, the filtrate was evaporated in vacuo and the residue was recrystallized from carbon tetrachloride, yielding 2.1 gm (46% of theory) of 5-ethyl-furo[3,2-d]isothiazole-3(2)-one-1,1-dioxide.
M.p.: 133° C.
C7 H7 NO4 S (201.21)--Calc. C-41.79%; H-3.51%; N-6.96%; S-15.84%; Found: C-41.53%; H-3.35%; N-6.97%; S-15.83%.
The starting compound was prepared in the following way:
Analogous to the preparation of the 5-methyl-2-sulfamoyl-furan-3-carboxylic acid (see starting compound of Example 1), 2-ethyl furan was sulfonated with sulfur trioxide-pyridine-complex into the sodium salt of the 5-ethyl-furan-2-sulfonic acid with a yield of 32.5% of theory. After chlorinating it with phosphorus pentachloride and reacting it with tert. butyl amine, 5-ethyl-N-tert. butyl-furan-2-sulfonamide [(m.p. 71°-72° C. from petroleum ether); 1H-NMR (CDCl3): δ=6.95 (d, 1, J=2 Hz, 3-H), 6.15 (d, 1, J=2 Hz, 4-H), 4,7 (s, 1, NH, exchangeable), 2.73 (q, 2, CH2), 1.30 (m, 12, --CH2 --CH3 and C(CH3)3)] was obtained with a yield of 48% of theory. The two subsequent reactions were also performed in analogy to the preparation of the 5-methyl-furan compound: By metalizing with butyl lithium and by carboxylating with carbon dioxide, the 5-ethyl-2-(N-tert. butyl)-sulfamoyl-furan-3-carboxylic acid (m.p. 118°-119° C. from cyclo hexane) was obtained with a yield of 59% of theory, which was heated under dry conditions at 160° C. for 2 hours. 5-Ethyl-2-sulfamoyl-furan-3-carboxylic acid [m.p.: 186° C. (from ethyl acetate), 1 H-NMR ([d6 ]=DMSO); δ=6.6 (s, 1, 4-H), 2.73 (q, 2, CH2), 1.25 (t, 3, CH3) and two exchangeable protons] was obtained with a yield of 87% of theory.
C7 H9 NO5 S (219.22)--Cal.: C-38.35%; H-4.14%; N-6.39%; S-14.63%; Found: C-38.33% H-4.04%; N-6.70%; S-14.56%.
A mixture of 1.0 gm (4.6 millimols) of 4.5 -dimethyl-2-sulfamoyl-furan-3-carboxylic acid and 0.96 gm (4.6 millimols) of phosphorus pentachloride in toluene was reacted analogous to Example 1, yielding 0.68 gm (73% of theory) of 4,5-dimethyl-furo[3,2-d]isothiazole-3-(2H)-one-1,1-dioxide. Rf -value: 0.21 (silica gel 60 F254 plates, thickness 0.25 mm, eluant ethylene chloride; ethyl acetate; glacial acetic acid 100:30:5).
C7 H7 NO4 S (201.21)--Calc.: C-41.79%; H-3.51%; N-6.96%; S-15.94%; Found: C-41.50% H-3.56%; N-6.92%; S-15.98%.
The starting compound was prepared in the following way:
Analogous to the preparation of the 5-methyl-2-sulfamoyl-furan-3-carboxylic acid (see starting compound of Example 1), 2,3-dimethyl-furan [K. C. Rice and J. R. Dyer, J. Heterocycl. Chem. 12, 1325 (1975)] was converted with sulfur trioxide-pyridine complex into the 4,5-dimethyl-furan-2-sulfonic acid sodium salt and treated with phosphorus pentachloride and tert. butylamine. N-tert. butyl-4-,5-dimethyl-furan-3-sulfonamide was obtained with a yield of 34% of theory. M.p. 95°-96° C. (from petroleum ether).
1H-NMR (CDCl3): δ=6.85 (s, 1, 3-H), 4,6 (s, 1, NH, exchangeable), 2.30 (s, 3, 5-CH3), 2.00 (s, 3, 4-CH3), 1.26 (s, 9, C(CH3)3).
By subsequent metalizing with butyl lithium and carboxylating with carbon dioxide, 4,5-dimethyl-2-(N-tert. butyl)-sulfamoyl-furan-3-carboxylic acid was obtained with a yield of 70%.
M.p. 114°-115° C. (from petroleum ether). By dry heating in vacuo this carboxylic acid was converted into 4,5-dimethyl-2-sulfamoyl-furan-2-carboxylic acid.
Yield 16% of theory.
C7 H9 NO5 S (219.22)--Calc: C-38.35% H-4.14%; N-6.39%; S-14.63%; Found: C-38.40%; H-4.01%; N-6.45%; S-14.50%.
0.5 gm (2.3 millimols) of 2-(tert. butyl)-4,5-dimethyl-furo[3,2-d]isothiazole-3(2H)-one-1,1-dioxide was heated in vacuo at 175° C. for 2 hours. After cooling, the reaction product was purified by column chromatography (eluant: ethylene chloride/ethyl acetate/glacial acetic acid, 100:30:5). 35 mgm (7.5% of theory) of 4,5-dimethyl-furo-3,2-d]-isothiazole-3(2H)-one-1, 1-dioxide were obtained.
C7 H7 NO4 S (201.21)--Calc: C-41.79%; H-3.51%; N-6.96%; S-15.94%; Found: C-41.60%; H-3.65%; N-7.02%; S-15.85%.
The starting compound was prepared in the following way:
1.7 gm (6.2 millimols) of 4,5-dimethyl-2-(N-tert. butyl)-sulfamoyl-furan-3-carboxylic acid were admixed with 5 gm of polyphosphoric acid, and the mixture was heated for 30 minutes at 60° C. After pouring it over ice, the reaction mixture was extracted with methylene chloride, the organic phase was washed with aqueous sodium bicarbonate and with water and then evaporated. 0.65 mgm (41% of theory) of 2-(tert. butyl)-4,5-dimethyl-furo[3,2-d]isothiazole-3(2H)-one-1,1-dioxide was obtained.
C11 H15 NO4 S (257.31)--Cal.: C-51.35%; H-5.88%; N-5.44%; S-12.46%; Found: C-51.20%; H-5.91%; N-5.32%; S-12.32%.
139 gm (0.5 mol) of 5-methyl-2-(N-tert. butyl) sulfamoyl-thiophene-3-carboxylic acid were added in portions to 500 ml of freshly prepared polyphosphoric acid cooled to 60° C. (prepared at 140° C. from 570 gm of phosphorus pentoxide and 250 ml of 85% phosphoric acid). The reaction mixture was stirred for 30 minutes at this temperature. After pouring over ice, the precipitated crude product was filtered off, washed with ice water and dried. After recrystallization from methanol 98.5 gm (97% of theory) of 5-methyl-thieno-[3,2-d]isothiazole -3(2H)-one-1,1-dioxide were obtained.
M.p.: 231° C. IR (KBr): 3200 (NH), 1740 (CO), 1325 and 1150 cm-1 (SO2), 1 H-NMR ([d6 ]-DMSO): δ=7.2 (d, 1, J=1 Hz, 4-H), 2,6 (d, 3, J=1 Hz, CH3) and 1 exchangeable proton.
C6 H5 NO3 S2 (203.23)--Calc.: C-35.46%; H-2.48%; N-6.89%; S-31.55%; Found: C-35.35% H-2.64%; N-7.10%; S-31.40%.
The starting compound was prepared in the following way:
291 gm (2.5 mol) of chlorosulfonic acid were added in portions to 208 gm (1.0 mol) of phosphorus pentachloride while stirring and cooling. After the evolution of hydrogen chloride had subsided, 98 gm (1.0 mol) of 2-methyl-thiophene were added dropwise while stirring at a temperature of 10° C. When the addition was finished, the mixture was stirred for another 10 minutes. After pouring the reaction mixture over 2.5 kg of ice, the obtained sulfochloride was separated by extracting 5 times with 500 ml of ether. The organic phase was washed twice with 200 ml of water, dried and evaporated in vacuo. The residual oil was taken up in 200 ml of tetrahydrofuran and added, while stirring, dropwise to a solution of 183 gm (2.5 mol) of tert. butylamine in 100 ml of tetrahydrofuran at a temperature of 20° C. The mixture was stirred for 1 hour at room temperature and for 20 minutes at 70° C. bath temperature. The crystals of tert. butylamine hydrochloride which separated out were filtered off and washed with ether. The combined filtrates were evaporated, and the residue was taken up in ether. After washing with 2 N hydrochloric acid and water, the residue was dried over sodium sulfate and again evaporated. The obtained crude product was recrystallized from cyclohexane, yielding 182 gm (78% of theory) of N-tert.-butyl-5-methyl-thiophene-2-sulfonamide.
M.p. 89° C.
117 gm (0.5 mol) of N-tert.butyl-5-methyl-thiophene-2-sulfonamide were dissolved in 1 liter of dried tetrahydrofuran and cooled to -40° C. In a nitrogen atmosphere 640 ml of a 15% solution of n-butyl-lithium in hexane (1.05 mol) were added dropwise to this solution, while keeping the temperature below -40° C. When the addition was finished, the mixture was stirred for 30 minutes at -20° C., cooled to -60° C. and a stream of carbon dioxide was passed over the reaction mixture. The strongly exothermic reaction was kept at -50° C. and when the reaction was finished, carbon dioxide passed over the mixture for another 10 minutes. The mixture was heated to -10° C., carefully acidified with concentrated hydrochloric acid (about 110 ml) and evaporated to dryness. The residue was taken up in ether (about 3 liters) and washed with water (about 2.5 liters).
After drying and evaporating of the ether phase, the crude product was recrystallized from benzene yielding 114 gm (82% of theory) of 5-methyl-2-(N-tert.butyl)-sulfamoyl-thiophene-3-carboxylic acid.
M.p. 178° C.
IR (CH2 Cl2): 1730 and 1690 cm-1 (CO), 1335 and 1160 (SO2);
1H-NMR (CDCl3 +CD3 OD: δ=7.2 (d, 1, J=0.5 Hz, 3-H) 2.52 (d, 3, J=0.5, CH3), 1.26 (s, 9, C(CH3)3), 2 exchangeable protons.
C10 H15 NO4 S2 (277.37)--Calc.: C-43.30%; H-5.45%; N-5.05%; S-23.12%; Found: C-43.50%; H-5.48%; N-4.91%; S-22.82%.
0.5 gm (2.26 millimols) of 5-methyl-2-sulfamoyl-thiophene-3-carboxylic acid was reacted analogous to Example 5(a), yielding 0.44 gm (96% of theory) of 5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide.
M.p. 231° C. (from methanol)
C6 H5 NO3 S2 (203.23)--Calc.: C-35.46%; H-2.48%; N-6.89%; S-31.55%; Found: C-35.50%; H-2.50%; N-6.78%; S-31.48%.
The starting compound was prepared in the following way:
A mixture of 5.0 gm (18 millimols) of 2-(N-tert.butyl)-sulfamoyl-5-methyl-thiophene-3-carboxylic acid and 20 ml of o-dichloro-benzene was heated, while stirring, for 4 hours at 140° C. After cooling, the reaction mixture was taken up in a mixture of ether and the equivalent amount of dilute aqueous sodium hydroxide. After separation of the ether phase, the aqueous phase was acidified with hydrochloric acid, and the precipitated material was suction-filtered off. The filter cake was recrystallized from ethyl acetate/cyclohexane, yielding 3.3 gm (83% of theory) of 5-methyl-2-sulfamoyl-thiophene-3-carboxylic acid.
M.p.: 198° C.
C6 H7 NO4 S2 (221.26)--Calc.: C-32.57%; H-3.19%; N-6.33%; S-28.98%; Found: C-32.89%; H-3.30%; N-6.34%; S-28.90%.
A mixture of 0.5 gm (2.26 millimols) of 5-methyl-2-sulfamoyl-thiophene-3-carboxylic acid, 0.5 gm (2.2 millimols) of phosphorus pentachloride and 30 ml of anhydrous toluene was refluxed for 9 hours. The mixture was worked up in analogy to Example 1 and yielded 0.41 gm (89% of theory) of 5-methyl-thieno[3,2-d]isothiazole-3-(2H)-one-1,1-dioxide.
M.p. 231° C. (from methanol).
A mixture of 0.1 gm (0.45 millimols) of 5-methyl-2-sulfamoyl-thiophene-3-carboxylic acid, 50 ml of anhydrous toluene and 5 mgm of p-toluene-sulfonic acid was heated for 10 hours in a vessel equipped with a water trap. The reaction mixture was evaporated to dryness in vacuo and separated by column chromatography. 0.40 mgm (49% of theory) of 5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide were obtained.
M.p. 231° C. (from methanol).
A mixture of 0.2 gm (0.77 millimols) of N-tert.butyl-5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1-dioxide and o-dichloro-benzene was refluxed for 8 hours. After cooling, the reaction mixture was distributed between a mixture of ether and aqueous sodium bicarbonate solution. The separated aqueous solution was acidified and extracted with methylene chloride. After evaporation and recrystallization from methanol, 0.13 gm (83% of theory) of 5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide was obtained.
M.p. 231° C.
C6 H5 NO3 S2 (203.23)--Calc.: C-35.46%; H-2.48%; N-6.89%; S-31.55%; Found: C-35.50%; H-2.50%; N-6.78%; S-31.48%.
The starting compound was prepared as follows:
A mixture of 3.0 gm (10.8 millimols) of 2-(N-tert.butyl)-sulfamoyl-5-methyl-thiophene-3-carboxylic acid, 2.25 gm (10.8 millimols) of phosphorus pentachloride and 60 ml of toluene was refluxed for 7 hours. The reaction mixture was filtered while hot, cooled, and 300 ml of ether were added. The mixture was washed with an aqueous sodium bicarbonate solution and water, dried and evaporated. The residue was recrystallized from cyclohexane, yielding 1.5 gm (54% of theory) of 2-tert.butyl-5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide.
M.p.: 80°-81° C.
C10 H13 NO3 S2 (259.35)--Calc.: C-46.31%; H-5.05%; N-5.40%; S-24.73%; Found: C-46.39%; H-5.15%; N-5.44%; S-24.45%.
2.4 gm (10.2 millimols) of methyl 5-methyl-2-sulfamoyl-thiophene-3-carboxylate were added to a solution of 0.24 gm (10.2 millimols) of sodium in 50 ml of anhydrous methanol. After refluxing it for 4 hours the mixture was evaporated to dryness in vacuo. The residue was, as far as possible, dissolved in ethanol, and after suction filtering ether was added to the filtrate, 2.1 gm (91% of theory) of 5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide sodium salt crystallized out.
M.p. 325° C. (decomp.).
C6 H4 NNaO3 S2 (225.22)--Calc.: C-32.00%; H-1.79%; N-6.22%; S-28.47%; Found: C-32.00%; H-1.91%; N-6.13%; S-28.50%.
By dissolving the salt in water and acidifying the solution with hydrochloric acid the salt was converted into 5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide.
M.p. 231° C.
The starting compound was prepared as follows:
A mixture of 3.0 gm (13 millimols) of 5-methyl-2-sulfamoyl-thiophene-3-carboxylic acid and 150 ml of methanolic hydrochloric acid was stirred for 2 hours at room temperature and then refluxed for 2 hours. The reaction mixture was evaporated, and the residue was dissolved in ether. After washing with diluted aqueous sodium bicarbonate and with water, drying, evaporating in vacuo and recrystallization from methanol/water, 2.9 gm (95% of theory) of methyl 5-methyl-2-sulfamoyl-thiophene-3-carboxylate were obtained.
M.p.: 137°-138° C.
C7 H9 NO4 S2 (235.29)--Calc.: C-35.73%; H-3.86%; N-5.95%; S-27.25%; Found: C-36.20%; H-4.00%; N-5.95%; S-27.50%.
A solution of 4.0 gm (0.1 mol) of sodium hydroxide in 50 ml of water was added to a solution of 20.3 gm (0.1 mol) of 5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide in 500 ml of ethanol. The mixture was evaporated to dryness and the residue was recrystallized from ethanol/ether. 17.5 gm (78% of theory) of 5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide sodium salt were obtained.
M.p. 325° C. (decomp.).
IR (KBr): 1630 cm-1 (CO).
C6 H4 NNaO3 S2 (225.22)--Calc.: C-32.00%; H-1.79%; N-6.22%; S-28.47%; Found: C-32.20%; H-1.88%; N-6.01%; S-28.15%.
500 ml of methanol were added to 0.49 gm (12.3 millimols) of calcium, the mixture was refluxed, and 5.0 gm (24.6 millimols) of 5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide were added to the suspension thus obtained. The resulting solution was evaporated, and the residue was recrystallized from a little ethanol/ether. 3.9 gm (71% of theory) of 5-methyl-thieno[3,2-d]-isothiazole-3(2H)-one-1,1-dioxide calcium salt were obtained.
M.p. 306°-308° C. (decomp.).
C12 H8 CaN2 O6 S4 (444.55)--Calc.: C-32.42%; H-1.81%; N-6.31%; S-28.85%; Found: C-32.55%; H-2.05%; N-6.12%; S-28.88%.
Prepared analogous to Example 2(a) from 5-methyl-thieno-[3,2-d]isothiazole-3(2H)-one-1,1-dioxide and aqueous ammonia with a yield of 81% of theory.
M.p. 224° C. (from ethanol/ether).
C6 H8 N2 O3 S2 (220.28)--Calc.: C-32.72%; H-3.66%; N-12.72%; S-29.11%; Found: C-32.90%; H-3.46%; N-12.62%; S-29.20%.
Prepared analogous to Example 2(a) from 5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide and aqueous potassium hydroxide with a yield of 84% of theory.
M.p.: 297° C. (from ethanol/ether).
C6 H4 KNO3 S2 (241.34)--Calc.: C-29.86%; H-1.67%; N-5.80%; S-26.57%; Found: C-29.81%; H-1.74%; N-5.94%; S-26.35%.
42.0 gm (0.144 mol) of 5-ethyl-2(N-tert.butyl)-sulfamoyl-thiophene-3-carboxylic acid were added to 150 ml of polyphosphoric acid, and the mixture was heated at 80° C. for 20 minutes. The reaction mixture was poured over ice, and the precipitated crude product was filtered off, washed with ice and dried. After recrystallization from benzene and from ethyl acetate, 15.9 gm (51% of theory) of 5-ethyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide were obtained.
M.p. 143° C.
IR (CH2 Cl2): 3350 (NH), 1740 (CO), 1340 and 1150 cm-1 (SO2);
C7 H7 NO3 S2 (217.27)--Calc.: C-38.70%; H-3.25%; N-6.45%; S-29.52%; Found: C-38.50%; H-3.24%; N-6.33%; S-29.80%.
The starting compound was prepared in the following way:
222 gm (1.07 mol) of phosphorus pentachloride were added in portions while stirring and cooling to 310 gm (2.7 mol) of chlorosulfonic acid. After the evolution of hydrogen chloride had subsided, 100 gm (0.89 mol) of 2-ethyl-thiophene were added dropwise while stirring at a temperature of 20° C. When the addition was finished, the reaction mixture was poured over ice and extracted with ether. The ether solution was washed until neutral, dried and evaporated. The residue was taken up in tetrahydrofuran, and the solution was added dropwise to a solution of 169 gm (2.3 mol) of tert.butylamine in 200 ml of tetrahydrofuran. After refluxing for 3 hours, the reaction mixture was filtered to separate the precipitated tert.butylamine hydrochloride, and the filtrate was evaporated in vacuo. The residue was taken up in ether and the solution was washed with dilute hydrochloric acid and with water, dried and evaporated. 147 gm of crude product were obtained which, after purification on a silica gel column (4 kg of silica gel 40 for column chromatography, particle size 0.2-0.5 mm; eluant: cyclohexane/ethyl acetate 4:1), yielded 117.6 gm (53% of theory) of 5-ethyl-N-tert.butyl-thiophene-2-sulfonamide.
M.p. 38° C.
C10 H17 NO2 S2 (247.39)--Calc.: C-48.55%; H-6.93%; N-5.66%; S-25.92%; Found: C-48.20%; H-6.86%; N-5.72%; S-25.60%.
56.8 gm (0.23 mol) of 5-ethyl-N-tert.butyl-thiophene-2-sulfonamide were dissolved in 500 ml of dried tetrahydrofuran, and the solution was cooled to -20° C. 310 ml of a 15% solution of n-butyl-lithium (0.5 mol) in hexane were added dropwise at this temperature. After stirring for 2 hours, the reaction mixture was poured over solid carbon dioxide (dry ice), evaporated and distributed between water and ether. The aqueous phase was acidified and extracted with ether. The ether extract was evaporated, and the residue was recrystallized from cyclohexane/petroleum ether. 42 gm (63% of theory) of 5-ethyl-2-(N-tert.butyl)-sulfamoyl-thiophene-3-carboxylic acid were obtained.
M.p. 135° C.
C11 H17 NO4 S2 (291.40)--Calc.: C-45.34%; H-5.88%; N-4.81%; S-22.01%; Found: C-45.40%; H-5.91%; N-4.90%; S-22.00%.
10.5 gm (48 millimols) of 5-ethyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide were dissolved in ethanol. The solution was adjusted to pH 7 with aqueous sodium hydroxide. After evaporating the solution in vacuo and recrystallizing the residue from tetrahydrofuran, 6.6 gm (57.5% of theory) of 5-ethyl-thieno[3,2-d]-isothiazole-3(2H)-one-1,1-dioxide sodium salt were obtained.
M.P. 273°-275° C. (decomp.).
C7 H6 NNaO3 S2 (239.26)--Calc.: C-35.41%; H-2.53%; N-5.86%; S-26.80%; Found: C-34.90%; H-2.67%; N-5.69%; S-26.70%.
20.0 gm (68.6 millimols) of 2-(N-tert.butyl) sulfamoyl-4,5-dimethyl-thiophene-3-carboxylic acid were added to 100 ml of polyphosphoric acid, and the mixture was heated at 80° C. for 1 hour. Subsequently, the reaction mixture was poured over ice, and the raw product which crystallized out (14 gm) was filtered off, dried and recrystallized twice from benzene. 12.5 gm (84% of theory) of 4.5-dimethyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide were obtained.
M.p. 187° C.
IR (CH2 Cl2): 3350 (NH), 1730/1720 (CO), 1340 and 1175 cm-1 (SO2).
1H-N MR (CDCl3): δ=7.5 (1, NH, exchangeable), 2,5 (3, s, 5-CH3), 2.35 (3, s, 4-CH3).
C7 H8 NO3 S2 (217.27)--Calc.: C-38.70%; H-3.25%; N-6.45%; S-29.52%; Found: C-38.50%; H-3.21%; N-6.39%; S-29.35%.
The starting compound was prepared as follows: 22.0 gm (0.196 mol) of 2,3-dimethyl-thiophene were converted into 25.0 gm of N-tert.butyl-4,5-dimethyl-thiophene-2-sulfonamide in analogy to the conversion of 2-ethyl-thiophene (see starting compound of Example 7) with chlorosulfonic acid/phosphorus pentachloride via 4,5-dimethyl-thiophene-2-sulfonic acid chloride and then with tert.butylamine. Yield: 51.5% of theory.
M.p. 102° C. (from petroleum ether).
1H-NMR (CDCl3): δ=7.35 (s, 1,3-H), 4.8 (s, 1, NH, exchangeable), 2.45 (s, 3, 5-CH3), 2.2 (s, 3, 4-CH3), 1.35 (s, 9, C(CH3)3);
C10 H17 NO2 S2 (247.39)--Calc.: C-48.55%; H-6.93%; N-5.66%; S-25.92%; Found: C-48.40%; H-6.97%; N-5.66%; S-25.70%.
The subsequent reactions with n-butyl-lithium in tetrahydrofuran at temperatures between -60° C. to -20° C. and with carbon dioxide, also at -60° C. to -20° C., produced a yield of 26.3 gm (90% of theory) of 2-(N-tert.butyl) sulfamoyl-4,5-dimethyl-thiophene-3-carboxylic acid.
M.p. 193°-194° C. (from benzene).
IR (KBr); 3230 (NH and OH), 1725 and 1710 (CO), 1310 and 1130 cm-1 (SO2);
1H-NMR (CDCl3 +CD3 OH): δ=2.4 (s, 3, 5-CH3), 2.28 (s, 3, 4-CH3), 1.3 (s, 9, C(CH3)3) and 2 exchangeable protons.
3.0 gm (13.8 millimols) of 4,5-dimethyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide were dissolved in an aqueous solution of 1.16 gm (13.8 millimols) of sodium bicarbonate in 50 ml of water. The resulting solution was evaporated in vacuo, and the residue was recrystallized from ethanol. 2.5 gm (76% of theory) of 4,5-dimethyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide sodium salt were obtained.
M.p. above 250° C. (decomp.)
C7 H6 NNaO3 S2 (239.26)--Calc.: C-35.14%; H-2.59%; N-5.85%; S-26.80%; Found: C-35.40%; H-2.70%; N-5.88%; S-26.90%.
37 mgm (0.5 millimols) of calcium hydroxide and 217 mgm (1 millimol) of 4,5-dimethyl-thieno[3,2-d]isothiazole-3-(2H)-one-1,1-dioxide were added to 50 ml of boiling water. The virtually clear resulting solution was filtered and evaporated to 1 ml. 180 mg (76% of theory) of 4,5-dimethyl-thieno[3,2-d]-isothiazole-3(2H)-one-1,1-dioxide calcium salt crystallized out.
M.p. >320° C. (decomp.)
C14 H12 N2 O6 S4 Ca (472.61)--Calc.: C-35.58%; H-2.56%; N-5.93%; S-27.14%; Found: C-35.30%; H-2.71%; N-5.74%; S-26.84%.
A mixture of 3.05 gm (10 millimols) of 4-ethyl-5-methyl-2-(N-tert.butyl)-sulfamoyl-thiophene-4-carboxylic acid and 20 ml of polyphophoric acid was heated at 65° C. for 30 minutes. Subsequently, the reaction mixture was poured over ice, and the resulting crystalline precipitate was filtered off, washed with ice water and dried. 2.1 gm (91% of theory) of 4-ethyl-5-methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide were obtained.
Rf -value: 0.19 (TLC-prefabricated plates, silica gel 60 F254, thickness of the layer 0.25 mm; eluant:ethylene chloride/ethyl acetate/glacial acetic acid 100:30:5).
C8 H9 NO3 S2 (231.29)--Calc.: C-41.54%; H-3.92%; N-6.06%; S-27.73%; Found: C-41.35%; H-3.90%; N-6.14%; S-27.62%.
The starting compound was prepared as follows:
3-ethyl-2-methyl-thiophene [W. Steinkopf, A. Merckoll and H. Straunch, Liebigs Ann. Chem. 545,45 (1940)] was reacted, analogous to 2-methyl-thiophene (see Example 5) with phosphorus pentachloride and chlorosulfonic acid, and the resulting sulfochloride was treated with tert.butylamine. By metalizing with n-butyl-lithium and carboxylating with carbon dioxide, also in analogy to the preparation of 5-methyl-2-(N-tert.butyl) sulfamoyl-thiophene-3-carboxylic acid, 4-ethyl-5-methyl-2-(N-tert.butyl) sulfamoyl-thiophene-3-carboxylic acid was obtained. Rf -value: 0.27 (TLC-prefabricated plates, silica gel 60 F254, thickness of the layer 0.25 mm, eluant:ethylene chloride/ethyl acetate/glacial acetic acid 100:30:5);
C12 H19 NO4 S2 (305.42)--Calc.: C-47.19%; H-6.27%; N-4.59%; S-21.00%; Found: C-46.95%; H-6.31%; N-4.52%; S-20.92%.
As indicated above, the compounds of the present invention, that is, those embraced by formula I and their non-toxic salts, are useful as sweetening agents.
Our discovery that the compounds of the present invention are very powerful sweetening agents is unobvious and surprising inasmuch as 5-methyl-saccharin, which comprises a --CH═CH-group in place of the heteroatom--X-- in formula I, and its alkali metal salts possess no sweetening power comparable to saccharin, although it is well known that a --CH═CH-- group is virtually equivalent in its effect on the ring system to an --S-- group, for example. It had to be assumed, therefore, that the compounds of this invention would be considerably inferior with respect to their sweetening power to thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide.
The condensed isothiazole-3(2H)-one-1,1-dioxides of the formula I above are, from the chemical viewpoint, closely related to the thieno isothiazolone dioxides disclosed in German Offenlegungsschrift No. 2,534,689, but they are distinguishable over the prior art compounds because of the following advantageous properties:
(a) The alkyl substituent R2 in the molecule of the dioxides of the present invention significantly contributes toward an improvement in taste; for instance, they do not have the unpleasant after-taste associated with saccharin. Moreover, the presence of the alkyl group in the 5-position provides a different metabolization route, wherefore the novel compounds exhibit a different toxicologic and metabolic behavior.
(b) The dioxides of the instant invention are considerably more readily accessible, because the α-positioned alkyl group in the thiophene or furan starting compound makes it easy to introduce a sulfo group in the α'-position and a carboxyl group in the β'-position with high yields and great purity of the end product.
(c) The sweetening power is stronger.
The compounds of the present invention were tested for sweetening power in comparison to certain prior art compounds, as well as for pharmacological effects, toxicity and mutagenic effects, as described below, and the results of these tests for a few representative species were as follows, where
A=5-Methyl-furo[3,2-d]isothiazole-3-(2H)-one-1,1-dioxide,
B=5-Methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide,
C=5-Methyl-thieno[3,2-d]isothiazole-3-(2H)-one-1,1-dioxide sodium salt,
D=5-Methyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide calcium salt,
E=4,5-Dimethyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide,
F=4,5-Dimethyl-thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide sodium salt,
U--Cyclamate,
V=Saccharin,
W=Saccharin sodium and
X=Thieno[3,2-d]isothiazole-3(2H)-one-1,1-dioxide.
From novel compounds A, B, C, D, E and F and from known comparison compounds U, V and W aqueous solutions in concentrations of 1:12500, 1:25000, 1:50000, 1:100000 and 1:200000 were prepared and evaluated by each of 5 taste testers according to the following criteria: Very sweet (=3 points); medium sweet (=2 points), slightly sweet (=1 point) and not sweet (=0 point). The tests were carried out according to the method of H. G. Schutz and F. J. Pilgrim [Food Research 22, 206 (1957)]. The dilution with perceptible sweetness was defined as the concentration at which the average value reached the evaluation points 1.0 or higher.
The following table shows the results obtained:
______________________________________
Dilution with
Average Value of
Perceptible
Compound Concentration
Evaluation Points
Sweetness
______________________________________
Invention:
A 1:12500 1.4 1:12500
1:25000 0.2
B 1:25000 2.2 1:50000
1:50000 1.4
1:100000 0.2
C 1:25000 2.0 1:50000
1:50000 1.2
1:100000 0.2
D 1:25000 1.8 1:50000
1:50000 1.0
1:100000 0.0
E 1:50000 2.2 1:100000
1:100000 1.6
1:200000 0.4
F 1:50000 2.0 1:100000
1:100000 1.4
1:200000 0.2
Prior Art
U 1:12500 0.4 >1:12500
V 1:25000 2.4 1:50000
1:50000 1.2
1:100000 0.4
W 1:25000 2.2 1:50000
1:50000 1.2
1:100000 0.0
______________________________________
The relative sweetening power (often also defined as degree of sweetness) of sweetening agents in comparison to saccharose (cane sugar) varies with the concentrations within wide limits. Thus, in the usual concentrations (corresponding to a 2-10% solution of saccharose) the relative sweetening power of saccharin varies from 200 to 700. Therefore, for the determination of the relative sweetening power of the above-mentioned compounds a 3% aqueous solution of saccharose was always used for comparison.
The further determination of the relative sweetening power was continued according to the methods of R. Pauli [Chemiker-Zeitung 44, 744 (1920)] and T. Paul [Chemiker-Zeitung 45, 38 (1921)]. Each test series was tested by 4 taste testers.
The obtained results are given in the following table:
______________________________________
Relative Sweetening Power
Compound (Saccharose = 1)
______________________________________
Invention:
A 150
B 550
C 550
D 500
E 1050
F 1000
Prior Art
U 60
V 550
W 550
X 350+
______________________________________
+ This value is given on page 6 of the German Offenlegungsschrift
2,534,689).
The sweetening agents heretofore known, especially saccharin, do not have the taste quality of saccharose. They often have a side-taste or after-taste. Novel compounds A to F are, however, characterized by a very pure sweet taste. The compounds A and C achieve the taste quality of saccharose (cane sugar).
The compounds of the formula I were further tested with regard to possible pharmacological effects and with regard to their acute toxicity and their possible mutagenic effects.
Compound C was tested by the following pharmacological tests:
The substance shows no muscle-relaxing and coordination inhibitory effects in mice; even at dosages of 200 mgm/kg p.o. the mice were able to hold themselves in rotating cylinders. At the same dosage the motility of mice was tested in light beam cages; here it could also be determined that compound C does not influence the spontaneous motility of mice.
Also, the test of the motility of rats in electric activity cages according to Fuhrer and Feldhofer [Arzneim. Forsch. 11, 1027, (1961)] did not show any effect on the spontaneous motility of the rats. Moreover, no effect regarding the body temperatures of the rats at a dosage of 200 mg/kg p.o. could be observed. The measurements were made after 1, 2, 3 and 4 hours after oral administration of the substance; one control group only received the distilled water solvent.
Compound C has no effect on the hexobarbital narcosis in mice. At a dose of 25 mgm/kg p.o. the duration of the loss of the righting reflex was tested; the duration of the narcosis was not influenced.
At dosages of 200 mgm/kg p.o. the stimulation of the root of the tail by means of a tail clamp according to Haffner on mice did not show any influence on the defensive reactions to the pain stimuli.
Compound C also does not influence the electroshock convulsion in mice (dosage 200 mgm/kg p.o.). It also has no influence on the hypothermia of male mice, which is caused by reserpine. Compound C does not cause any ulcerations in the intestinal tract of the rat when 3 times 200 mgm/kg p.o. of the substance are administered. The test regarding the local compatibility in the eye of the rabbit showed the following result: a 1% solution causes no mydriasis, no redness of the conjunctiva and no local anesthesia.
The compound C had no effect on the contractility and the frequency of the isolated, beating atrium of the rat heart. When compound C was given in doses of 1.0 and 3.0 and 10.0 mg/kg i.v. no effect on blood pressure, heart rate and respiration of anesthetized cats could be observed. At concentrations of 1×10-4 mol/liter compound C had no effect on the ADP-induced, thrombine-induced and collagen-induced aggregation of the thrombozytes in the platelet-rich plasma of healthy test persons. The measurement of the secretion of Na+, K+, Cl- and liquid in water-loaded male rats showed no effect by compound C (dosage 200 mgm/kg p.o.) Compound C is neither bacteriostatically nor fungistatically effective.
The acute toxicity was determined after oral administration to male and female mice and to male and female rats. The substances were given in an aqueous solution or as a suspension in tylose. The following table shows the animals which died within 1 to 7 days after administration of the doses indicated:
______________________________________
Animals which
died within the
Dose Kind of Number of observ. time of
Compound mgm/kg animal animals 1 day 7 days
______________________________________
A 1000 mouse 6 0 0
B 5000 mouse 6 0 0
C 5000 rat 6 0 0
D 5000 mouse 6 0 0
E 1000 mouse 6 0 0
______________________________________
During the observation time no toxic symptoms could be observed in the animals. All animals survived and showed a completely normal behavior.
The most important requirement of sweetening agents is that these substances must be harmless and safe. Most of the sweetening agents however, do not meet with this requirement. Thus, for example, saccharin shows a mutagenic effect [R. P. Batzinger, S.-Y. L. On and E. Bueding, Science 198, 944 (1977)], which casts a doubt on its use as a sweetening agent.
Compounds C and D were tested in the AMES-system [Mutation Research 31, 347-364 (1975)] with regard to their mutagenic properties. In order to show the whole spectrum of induced molecular DNA-damages (base substitutions, frame-shift mutations, deletions) the auxotrophic bacterial strains Salmonella typhimurium TA 98, TA 100 and Escherichia coli WP 2 (P) were used as genetic indicators. The strains Salmonella typhimurium Ta 1535, TA 1537 and TA 1538 were additionally used in the test of compound C.
The tests for all microorganisms were carried out in a way such that the influence of a microsomal enzyme system, together with the corresponding co-factors, could be tested with regard to the test substance, and to determine the differences in enzyme induction. The tests were performed without an activating system and in the presence of an activating system. For the in vitro-activation, S-9 supernatants (fraction of the endoplasmatic reticulum) of normal, i.e. not pre-treated rats and of Aroclor 1254 (500 mg/kg) induced rats were used. From the S-9 induced fraction, 3 different concentration levels were tested.
The substance concentrations of compound C were 0.1 and 0.5 mgm/plate and the concentrations of compound D were 5, 10, 15 and 20 mg/plate. In a previous series dilution essay, the highest dosages still did not show any inhibition of the microorganism growth.
Compounds C and D did not lead to an increase in the spontaneous mutation rate in any of the tested strains. An effect of the enzyme induction and of the activating fraction on the reverse mutation rate was not detectable. The colonies counted on the substance plates were within the spontaneous range of each of the test strains.
The experiments showed that compounds C and D do not release base substitutions (S. typhimurium TA 1535, TA 100, E. coli WP2 (P) and frame-shift mutations (S. typhimurium TA 1537, TA 1538, TA 98), and therefore do not indicate a mutagenic potential for compounds C and D.
For use as sweetening agents for foods and beverages the compounds of the present invention are incorporated into conventional sugar-substitute compositions, such as tablets, powders or solutions, in amounts sufficient to provide the desired sweetening power.
The following examples illustrate a few such sweetening compositions containing a compound of the instant invention as a sweetening ingredient and represent the best modes contemplated of using the invention. The parts are parts by weight unless otherwise specified.
The solution is compounded from the following ingredients:
______________________________________ Sodium salt of 5-methyl-thieno- [3,2-d]isothiazole-3(2H)-one- 1,1-dioxide 2.0-parts Sorbic acid 0.1 parts Citric acid 1.2 parts Disodium phosphate 1.5 parts Distilled water 100.0 parts by vol. ______________________________________
The sweetening ingredient, the sorbic acid, the citric acid and the disodium phosphate are successively dissolved in the distilled water at 60° C. while stirring. 1 ml (corresponding to about 20 drops) of the solution contains 20 mgm of the sweetening ingredient and is equal in sweetening power to about 2 lumps of sugar.
The tablet composition is compounded from the following ingredients:
______________________________________
4,5-Dimethyl-thieno[3,2-d]-
isothiazole-3(2H)-one-1,1-dioxide
5.0 parts
Sodium bicarbonate 2.5 parts
Sorbitol, powdered 42.5 parts
Total 50.0 parts
______________________________________
The sweetening ingredient is intimately admixed with the sodium bicarbonate and the sorbitol, and the mixture is compressed at no more than 60% relative humidity into 50 mgm-tablets. Each tablet contains 5 mgm of the sweetening ingredient and is equivalent in sweetening power to about one lump of sugar.
Any one of the other compounds embraced by formula I or a non-toxic salt thereof may be substituted for the particular sweetening ingredient in Examples 12 and 13. Likewise, the amount of sweetening ingredient in these illustrative examples may be varied to achieve the desired sweetening power, and the amounts and nature of the inert carrier ingredients may be varied to meet particular requirements.
While the present invention has been illustrated with the aid of certain specific embodiments thereof, it will be readily apparent to others skilled in the art that the invention is not limited to these particular embodiments, and that various changes and modifications may be made without departing from the spirit of the invention or the scope of the appended claims.
Claims (3)
1. 4,5-Dimethyl-thieno[3,2-d]isothazole-3(2H)-one-1,1-dioxide or a non-toxic salt thereof formed with an inorganic or organic base.
2. A sweetening composition for foods and beverages consisting essentially of an inert carrier and an effective sweetening amount of a compound of claim 1.
3. The method of sweetening foods and beverages which composes adding thereto an effective sweetening amount of a compound of claim 1.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2749640 | 1977-11-05 | ||
| DE19772749640 DE2749640A1 (en) | 1977-11-05 | 1977-11-05 | Furo and thieno (3,2-d)-isothiazole-3-one-1,1-di:oxide(s) - artificial sweetening agents with high activity and low toxicity and side effects |
| DE19782839266 DE2839266A1 (en) | 1978-09-09 | 1978-09-09 | Furo and thieno (3,2-d)-isothiazole-3-one-1,1-di:oxide(s) - artificial sweetening agents with high activity and low toxicity and side effects |
| DE2839266 | 1978-09-09 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06107266 Division | 1979-12-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4233333A true US4233333A (en) | 1980-11-11 |
Family
ID=25773036
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/952,958 Expired - Lifetime US4233333A (en) | 1977-11-05 | 1978-10-20 | 4,5-Dimethyl-thieno[3,2-d]isothiazolo-3(2H)-one-1,1-dioxides, compositions, and methods of use as a sweetener |
| US06/297,004 Expired - Fee Related US4430355A (en) | 1977-11-05 | 1981-08-27 | Condensed isothiazolo-3 (2H)-one-1-1-dioxides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/297,004 Expired - Fee Related US4430355A (en) | 1977-11-05 | 1981-08-27 | Condensed isothiazolo-3 (2H)-one-1-1-dioxides |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US4233333A (en) |
| JP (1) | JPS5473792A (en) |
| AT (1) | AT364852B (en) |
| CA (1) | CA1112646A (en) |
| CH (1) | CH638222A5 (en) |
| DK (1) | DK490678A (en) |
| ES (1) | ES474600A1 (en) |
| FI (1) | FI63416C (en) |
| FR (1) | FR2407934A1 (en) |
| GB (1) | GB2007227B (en) |
| GR (1) | GR65280B (en) |
| HU (1) | HU179354B (en) |
| IE (1) | IE47488B1 (en) |
| IL (1) | IL55868A (en) |
| IT (1) | IT1157400B (en) |
| LU (1) | LU80472A1 (en) |
| NL (1) | NL7810949A (en) |
| NO (1) | NO149355C (en) |
| NZ (1) | NZ188818A (en) |
| PH (1) | PH14846A (en) |
| PT (1) | PT68743A (en) |
| SE (1) | SE7811418L (en) |
| YU (1) | YU254078A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4430355A (en) | 1977-11-05 | 1984-02-07 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Condensed isothiazolo-3 (2H)-one-1-1-dioxides |
| US5512684A (en) * | 1994-07-22 | 1996-04-30 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxy-benzoyl) benzo B!-thiophenes |
| US5969157A (en) * | 1996-11-19 | 1999-10-19 | Eli Lilly And Company | Process for the synthesis of benzothiophenes |
| US5977383A (en) * | 1996-09-25 | 1999-11-02 | Eli Lilly And Company | Process for the synthesis of benzothiophenes |
| WO2017079719A1 (en) | 2015-11-06 | 2017-05-11 | Regents Of The University Of Minnesota | Aromatic surfactants |
| WO2017079718A1 (en) | 2015-11-06 | 2017-05-11 | Regents Of The University Of Minnesota | Methods of forming aromatic containing compounds |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK169255B1 (en) * | 1983-02-22 | 1994-09-26 | American Home Prod | Analogous Process for the preparation of thieno-isothiazole-1,1-dioxide derivatives and pharmaceutically acceptable salts thereof |
| CA1257262A (en) * | 1985-05-20 | 1989-07-11 | George Levitt | Herbicidal thiophenesulfonamides |
| FI862513L (en) * | 1985-07-04 | 1987-01-05 | Chemie Linz Ag | NYA TIENO-1,2-THIAZOLDERIVAT, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DESSA INNEHAOLLANDE FARMACEUTISKA PREPARAT. |
| US4732984A (en) * | 1985-10-17 | 1988-03-22 | American Home Products Corporation | Piperazinoisothiazolones with psychotropic activity |
| ATA39088A (en) * | 1988-02-18 | 1990-06-15 | Binder Dieter Dr | BASICALLY SUBSTITUTED THIENOISOTHIAZOL-3 (2H) -ON-1,1-DIOXIDES AND THEIR PHARMACEUTICALLY COMPATIBLE SALTS, METHOD FOR THE PRODUCTION AND THEIR USE |
| DE4427996A1 (en) * | 1994-08-08 | 1996-02-15 | Basf Ag | Process for the preparation of saccharin carboxylic acids and carboxylic acid esters |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2534689C3 (en) | 1974-09-16 | 1979-10-18 | Basf Ag, 6700 Ludwigshafen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT364852B (en) | 1977-11-05 | 1981-11-25 | Thomae Gmbh Dr K | METHOD FOR PRODUCING CONDENSED ISOTHIAZOL-3 (2H) -ON-1,1-DIOXIDES AND THEIR SALTS |
-
1978
- 1978-10-03 AT AT0711178A patent/AT364852B/en not_active IP Right Cessation
- 1978-10-20 US US05/952,958 patent/US4233333A/en not_active Expired - Lifetime
- 1978-10-27 ES ES474600A patent/ES474600A1/en not_active Expired
- 1978-10-31 GR GR57539A patent/GR65280B/en unknown
- 1978-11-01 CH CH1126078A patent/CH638222A5/en not_active IP Right Cessation
- 1978-11-01 YU YU02540/78A patent/YU254078A/en unknown
- 1978-11-02 CA CA315,728A patent/CA1112646A/en not_active Expired
- 1978-11-03 NO NO783699A patent/NO149355C/en unknown
- 1978-11-03 FR FR7831223A patent/FR2407934A1/en active Granted
- 1978-11-03 IT IT51769/78A patent/IT1157400B/en active
- 1978-11-03 NL NL7810949A patent/NL7810949A/en not_active Application Discontinuation
- 1978-11-03 HU HU78TO1088A patent/HU179354B/en unknown
- 1978-11-03 DK DK490678A patent/DK490678A/en not_active Application Discontinuation
- 1978-11-03 GB GB7843073A patent/GB2007227B/en not_active Expired
- 1978-11-03 NZ NZ188818A patent/NZ188818A/en unknown
- 1978-11-03 FI FI783357A patent/FI63416C/en not_active IP Right Cessation
- 1978-11-03 LU LU80472A patent/LU80472A1/en unknown
- 1978-11-03 IE IE2185/78A patent/IE47488B1/en unknown
- 1978-11-03 IL IL55868A patent/IL55868A/en unknown
- 1978-11-03 SE SE7811418A patent/SE7811418L/en unknown
- 1978-11-03 PT PT68743A patent/PT68743A/en unknown
- 1978-11-03 PH PH21761A patent/PH14846A/en unknown
- 1978-11-06 JP JP13662878A patent/JPS5473792A/en active Pending
-
1981
- 1981-08-27 US US06/297,004 patent/US4430355A/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2534689C3 (en) | 1974-09-16 | 1979-10-18 | Basf Ag, 6700 Ludwigshafen |
Non-Patent Citations (1)
| Title |
|---|
| Lombardino, J. G. J. Org. Chem., vol. 36, No. 13, 1971 pp. 1843-1845. * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4430355A (en) | 1977-11-05 | 1984-02-07 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Condensed isothiazolo-3 (2H)-one-1-1-dioxides |
| US5512684A (en) * | 1994-07-22 | 1996-04-30 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxy-benzoyl) benzo B!-thiophenes |
| US5523416A (en) * | 1994-07-22 | 1996-06-04 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes |
| US5977383A (en) * | 1996-09-25 | 1999-11-02 | Eli Lilly And Company | Process for the synthesis of benzothiophenes |
| US5969157A (en) * | 1996-11-19 | 1999-10-19 | Eli Lilly And Company | Process for the synthesis of benzothiophenes |
| WO2017079719A1 (en) | 2015-11-06 | 2017-05-11 | Regents Of The University Of Minnesota | Aromatic surfactants |
| WO2017079718A1 (en) | 2015-11-06 | 2017-05-11 | Regents Of The University Of Minnesota | Methods of forming aromatic containing compounds |
| US20180327375A1 (en) * | 2015-11-06 | 2018-11-15 | Christoph Krumm | Aromatic surfactants |
| US10618881B2 (en) | 2015-11-06 | 2020-04-14 | Regents Of The University Of Minnesota | Methods of forming aromatic containing compounds |
| US11236057B2 (en) * | 2015-11-06 | 2022-02-01 | Regents Of The University Of Minnesota | Aromatic surfactants |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5473792A (en) | 1979-06-13 |
| NZ188818A (en) | 1981-01-23 |
| PT68743A (en) | 1978-12-01 |
| IT1157400B (en) | 1987-02-11 |
| NO149355B (en) | 1983-12-27 |
| HU179354B (en) | 1982-10-28 |
| FR2407934A1 (en) | 1979-06-01 |
| IL55868A0 (en) | 1979-01-31 |
| IE47488B1 (en) | 1984-04-04 |
| GR65280B (en) | 1980-07-31 |
| FI783357A7 (en) | 1979-05-06 |
| SE7811418L (en) | 1979-05-06 |
| YU254078A (en) | 1983-01-21 |
| NO783699L (en) | 1979-05-08 |
| NL7810949A (en) | 1979-05-08 |
| GB2007227B (en) | 1982-03-24 |
| NO149355C (en) | 1984-04-04 |
| DK490678A (en) | 1979-05-06 |
| CA1112646A (en) | 1981-11-17 |
| ATA711178A (en) | 1981-04-15 |
| IE782185L (en) | 1979-05-05 |
| CH638222A5 (en) | 1983-09-15 |
| IT7851769A0 (en) | 1978-11-03 |
| ES474600A1 (en) | 1979-03-16 |
| GB2007227A (en) | 1979-05-16 |
| PH14846A (en) | 1981-12-16 |
| FI63416C (en) | 1983-06-10 |
| FI63416B (en) | 1983-02-28 |
| IL55868A (en) | 1981-07-31 |
| US4430355A (en) | 1984-02-07 |
| AT364852B (en) | 1981-11-25 |
| FR2407934B1 (en) | 1982-10-01 |
| LU80472A1 (en) | 1979-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4233333A (en) | 4,5-Dimethyl-thieno[3,2-d]isothiazolo-3(2H)-one-1,1-dioxides, compositions, and methods of use as a sweetener | |
| EP0045281B1 (en) | Triazoline derivatives and processes for their preparation | |
| DE19934433A1 (en) | New N-(indolyl-carbonyl)-N'-ethyl-piperazine derivatives, are 5-HT-2A receptor antagonists useful e.g. for treating schizophrenia, depression, Parkinson's disease, Alzheimer's disease or anorexia | |
| US3755583A (en) | Chas0!nhx | |
| GB2070606A (en) | 2(1h)-pyridinone derivatives their preparation and pharmaceutical compositions containing them | |
| JPH06506448A (en) | Novel active compounds | |
| NO744183L (en) | ||
| JPS62120388A (en) | Halogenated derivative of substance sf-2370 and production thereof | |
| US4301159A (en) | N-(Diethylaminoethyl)-2-alkoxy-benzamide derivatives | |
| KR900005278B1 (en) | Process for preparing substituted dibenzodiazepinones | |
| US3706747A (en) | Benzothieno(3,2-d)- and benzofuro(3,2-d)pyrimidines | |
| NO160080B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF A NEW THERAPEUTIC ACTIVE SYN-ISOMER OF A 3-VINYL-3-CEFEM COMPOUND AND PHARMASOEYTIC ACCEPTABLE SALTS AND ESTERS OF THEREOF. | |
| US4044130A (en) | Compositions for the control of microorganisms | |
| CA1218659A (en) | 1,3-dioxolo¬4,5-g|quinoline compounds | |
| US4183934A (en) | 4-Hydroxy-7-(substituted)phenylpteridines | |
| EP0124208B1 (en) | Quinoline derivatives | |
| US4235895A (en) | Substituted 5H-dibenz[b,f]azepine | |
| US4455310A (en) | Quinolinecarboxylic acid derivative, and antibacterial agent containing said compound as active ingredient | |
| JPH02501926A (en) | Substituted azacyclohexyl derivatives | |
| US4404230A (en) | 4-Hydroxy-1,2-Benzisothiazol-3(2H)-one-1,1-dioxides and salts thereof | |
| US4539402A (en) | Quinazolinone derivatives | |
| CZ282419B6 (en) | BENZO(c)PHENANTHRIDINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | |
| KR810001175B1 (en) | Method for preparing concentrated isothiazolo-3 (2H) -one-1,1-dioxide | |
| US3954775A (en) | Thiazolo(5,4-f)quinoline-8-carboxylic acid derivatives | |
| US4020083A (en) | 5-(2-Aminophenyl)-s-triazoles |